Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.

Dr Lambert was appointed CEO on 24 June 2019 and Managing Director on 6 February 2020. John has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, he was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry he was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.

Dr Peach has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. He was appointed as an Independent Non-Executive Director on 2nd of September 2015.

Ms Bell has more than 30 years' experience in leading law firms, financial services and corporate treasury operations in Melbourne, London, Toronto, San Francisco and Brisbane.

Dr Tong is a NZ trained physician with more than 25 years' experience in the pharmaceutical and biotechnology industry. Dr Tong was appointed as a Non-Executive Director on 4th of May 2018 and Chairman on 25th May 2018.

Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 30 years. Dr Burns was originally appointed as a Non-Executive Director on 4th May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5th December 2022.